October 11, 2018
Otsuka Pharmaceutical Co., Ltd.
Proteus Digital Health
Otsuka and Proteus Digital Health Announce Expanded Collaboration Agreement to Advanced Digital Medicines for Mental Health
Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health, based in California, today announce the signing of an expanded global collaboration agreement that will strengthen the relationship between the two companies for the further development and commercialization of a portfolio of medicines including the ABILIFY MYCITE® (aripiprazole tablets with sensor) offering, which received NDA approval from the U.S. Food and Drug Administration in November 2017.
This arrangement reinforces both companies' continued commitment to provide new advancements in digital medicine products and care models to address the needs of patients suffering from severe mental illness. As part of the expanded collaboration, Otsuka made $88 million in related equity and other payments to Proteus. The expanded agreement covers the development and commercialization of digital medicines over the next five years.
Information in this news release was current as of the original release date.